Loading clinical trials...

COMPLETEDPHASE1

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

A Phase 1 Study Assessing the Effect of Carbamazepine, a P-Glycoprotein Inducer, on the Pharmacokinetics of AT-527 in Healthy Adult Subjects

NCT04784000•Atea Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in healthy adult subjects.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
•Females must have a negative pregnancy test at Screening and prior to dosing
•Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2
•Willing to comply with the study requirements and to provide written informed consent

Exclusion Criteria

•Pregnant or breastfeeding
•Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19
•Abuse of alcohol or drugs
•Use of other investigational drugs within 28 days of dosing
•Use of other prescription drugs with 28 days of dosing
•Other clinically significant medical conditions or laboratory abnormalities

Locations (1)

Atea Study Site

Montreal, Quebec, Canada

Key Dates

Start Date

March 1, 2021

Primary Completion Date

April 10, 2021

Completion Date

April 10, 2021

Last Updated

July 29, 2021

Enrollment

ACTUAL participants

Conditions

Healthy Volunteer Study

Interventions

Period 1: AT-527 550 mg

DRUG

Period 2: carbamazepine

DRUG

Period 3: AT-527 550 mg + carbamazepine

DRUG

Period 3: AT-527 1100 mg + carbamazepine

DRUG

Muscle Vibration as a Countermeasure Against Hypoactivity-induced

NCT07021079

Vibration TherapyHealthy Volunteer Study+1 more

View study

COMPLETEDPHASE1

A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects

NCT06636500

Healthy Volunteer StudyPain Management

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 29, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

Inclusion Criteria

Exclusion Criteria

Muscle Vibration as a Countermeasure Against Hypoactivity-induced

A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects

Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir

Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe

Ibuprofen Suspension Bioequivalence Study

A Study Comparing Three Formulations of Ibuprofen in Healthy Subjects